Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Antonio Becerra-Massare"'
Publikováno v:
Revista Espanola de Enfermedades Digestivas, Vol 109, Iss 3, Pp 236-236
Externí odkaz:
https://doaj.org/article/2dfca757694e41358857ee3e69f23179
Autor:
Mireia Domniguez Bastante, Esther Brea Gomez, Natalia Zambudio Carroll, Andrea Molina Raya, María Trinidad Villegas Herrera, Antonio Becerra Massare, Antonio Palomeque Jiménez, Maria Angeles Herrero Torres, Jesus Maria Villar del Moral
Publikováno v:
Transplantation Proceedings. 52:572-574
Liver grafts from donors after cardiac death (DCD) involve a risk of failure owing to warm ischemia, among other factors. To minimize this important issue, new systems like normothermic regional perfusion have arisen. We report an observational and u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf826fd8b1bf47c4c9e7c7105c15e86f
https://doi.org/10.1016/j.transproceed.2019.11.050
https://doi.org/10.1016/j.transproceed.2019.11.050
Autor:
Natalia Zambudio Carroll, Jesus Maria Villar del Moral, Irina Palomo Lopez, Esther Brea Gomez, Antonio Becerra Massare, Maria Angeles Herrero Torres, María Trinidad Villegas Herrera, Julio Santoyo Villalba, Mireia Dominguez Bastante, Andrea Molina Raya
Publikováno v:
Transplantation proceedings. 52(2)
Cholangiocarcinoma is the second most common neoplasm in the liver, with a very poor, short-term prognosis. Today, surgery associated with or without an adjuvant is the only curative treatment. Liver transplantation (LT) is the best treatment for hep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eac44b9cdd9c527e5b46c5549da8f33
https://pubmed.ncbi.nlm.nih.gov/32057500
https://pubmed.ncbi.nlm.nih.gov/32057500
Autor:
Patricia Abellán Alfocea, A. Medina, Eduardo Redondo Cerezo, Flor Nogueras López, Maria Angeles López Garrido, Eva Julissa Ortega Suazo, Antonio Becerra Massare, M. Dolores Espinosa Aguilar
Publikováno v:
Transplantation proceedings. 52(2)
Background Calcineurin inhibitors have been implicated in acute and chronic kidney disease after liver transplant (LT). Everolimus (EVR) is a mammalian target of rapamycin inhibitor efficacious in preventing acute cellular rejection while preserving
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d2b4a01a67139153a5aadd4ccfbc4c4
https://pubmed.ncbi.nlm.nih.gov/32035673
https://pubmed.ncbi.nlm.nih.gov/32035673
Publikováno v:
Revista Española de Enfermedades Digestivas v.109 n.3 2017
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Revista Espanola de Enfermedades Digestivas, Vol 109, Iss 3, Pp 236-236
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Revista Espanola de Enfermedades Digestivas, Vol 109, Iss 3, Pp 236-236
Liver transplantation is an effective treatment for many liver diseases, with a 5-year survival of about 70 %. However, development of de novo malignancies in these immunocompromised patients is becoming a frequent complication medium term. The annua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f04579bfc2d755003d8d70e12ce62447
https://pubmed.ncbi.nlm.nih.gov/28190365
https://pubmed.ncbi.nlm.nih.gov/28190365